SCHEMBL19902701

SCHEMBL19902701

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1ncn2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 1/20 0.40
SMYD3 Q9H7B4 1/20 0.38
ROCK1 Q13464 2/20 0.38
HTR4 Q13639 1/20 0.38
KAT2B Q92831 1/20 0.37
CYP2D6 P10635 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PDE4B Q07343 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
TSHR P16473 1/20 0.36
LIPG Q9Y5X9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452828 0.88 ROCK2 (0.56) ROCK2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL19902350 0.80 ALDH1A1 (0.57) ROCK2ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL19902334 0.80 ALDH1A1 (0.57) ROCK2ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL19902530 0.79 HTR4 (0.61) CYP3A4HTR4CYP2D6
SCHEMBL19902644 0.79 ROCK1 (0.56) ROCK2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL19902345 0.77 ROCK1 (0.53) ROCK2NPC1RAB9AROCK1KDM4E
SCHEMBL19902713 0.77 TNKS (0.50) ROCK2RAB9AALDH1A1CYP1A2CYP2C9
SCHEMBL19902639 0.76 KDM4E (0.51) ROCK2NPC1RAB9AALDH1A1KDM4E
SCHEMBL19902720 0.76 ALDH1A1 (0.43) ROCK2NPC1RAB9AALDH1A1CYP1A2
SCHEMBL19902689 0.76 ROCK2 (0.46) ROCK2NPC1RAB9AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK2 3/4885NPC1 2709/4885RAB9A 564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.